Johnson & Johnson contractor Emergent Biosolutions Inc plans to resume Covid-19 vaccine production at its Baltimore plant after getting approval from the US Food and Drug Administration (FDA), the Wall Street Journal reported late on Wednesday, citing a statement from the company and a FDA letter.
Production of J&J's Covid-19 vaccine at the Baltimore site was halted by US authorities in April following a discovery that ingredients from AstraZeneca's Covid-19 vaccine, also being produced at the plant at that time, contaminated a batch of J&J's vaccines.
J&J, Emergent and the FDA did not immediately respond to Reuters requests for comment
(Published 29 July 2021, 04:33 IST)
JOIN US